Clearside raises $20M; Egalet nixes Shionogi deal;

@FierceBiotech: Pfizer is shuttering another U.K. R&D outpost, ditching 120 jobs. Article | Follow @FierceBiotech

@JohnCFierce: Lilly pulls the plug on a massive insulin project in a blow to its diabetes pipeline. Story | Follow @JohnCFierce

@DamianFierce: this is good SEO. Link | Follow @DamianFierce

> Clearside Biomedical closed a $20 million Series C financing to support its work on micro-injected treatments for back-of-the-eye diseases. News

> Novo Nordisk ($NVO) filed for European approval for a fast-acting version of its insulin NovoLog. More

> Egalet ($EGLT) terminated its collaboration with Shionogi, regaining the rights to a Phase I hydrocodone treatment designed to discourage abuse. Release

Medical Device News

@FierceMedDev: Dx Digest: Report | Follow @FierceMedDev

@VarunSaxena2: I've never seen a team invent so many ways to lose as the Detroit Lions! I knew it was coming! Unsure of call but it's the Lions after all. | Follow @VarunSaxena2

@EmilyWFierce: Google Life Sciences CMO opens up about research plans. Story | Follow @EmilyWFierce

> NIH funds a trio of robots to improve health, life quality for the disabled. Report

> Troubled Insulet recalling additional 18 lots of wearable insulin pump due to needle failure. More

Pharma News

@FiercePharma: #ICYMI yesterday: $TEVA to divest $1B in assets to clear antitrust hurdles to Allergan deal: Reuters. Story | Follow @FiercePharma

@CarlyHFierce: Lyxumia's CV results may help Sanofi's case for approval, but they won't score it points against SGLT2s. Story | Follow @CarlyHFierce

> If Pfizer's consumer health unit goes up for grabs, Reckitt's interested, CEO says. More

> Cancer drug prices vary across the globe as countries strike deals with Big Pharma: Study. Report

> Sun to launch copy of Novartis' best-selling drug Gleevec Feb. 1. Story

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.